Answers are grounded in this paper and cite their sources.
Abstract ID 102431 Poster Board 289 Neuropathic pain is a form of chronic pain that develops as a consequence of damage to the nervous system. Treatment of neuropathic pain is often incompletely effective, and most available therapeutics have only moderate efficacy and present side effects that limit their use. Opioids are commonly prescribed for the management of neuropathic pain despite equivocal results in clinical studies and significant abuse potential. Thus, neuropathic pain represents an area of critical unmet medical and novel classes of therapeutics with improved efficacy and safety profiles are urgently needed. Novel antagonist of GPR55, KLS-13019, was screened in rat models of neuropathic pain and morphine discrimination. Peripheral neuropathy was induced in rats with once daily 1mg/kg paclitaxel injections for 4 days. Rats were then administered KLS-13019 or comparator drugs on day 7 in an acute dosing paradigm or days 7-10 in a chronic dosing paradigm and allodynia was assessed by a Von Frey test. Allodynia was reversed in a dose dependent manner in the rats treated with KLS-13019, with the highest dose reverting the response to pre-paclitaxel injection baseline levels with both I.P. and P.O. administration after acute dosing. In the chronic dosing paradigm, 4 consecutive doses of KLS-13019 completely reversed allodynia for the duration of the phenotype. Additionally, co-administration of KLS-13019 with paclitaxel prevented the allodynic phenotype from developing in the animals. Finally, in an effort to characterize the in vivo pharmacology of KLS-13019 compared to opioid-class drugs, rats were trained to discriminate between morphine and saline via alternative and mutually exclusive lever presses as the "correct response" to treatment. After training, rats dosed with KLS-13109 did not respond as though they had received morphine. Additionally, cell and biochemical assays have suggested that this anti-allodynic effect is related to inhibition of GPR55 mediated calcium signaling and may be independent of ERK phosphorylation or arrestin interaction. Molecular modeling and structure activity relationship studies provide rationale for GPR55 selectivity for KLS-13019 over structural analogue CBD. Together, these data suggest that KLS-13019 represents a new class of drug that would be potentially useful for the treatment of neuropathic pain. T32DA007237
No takes yet. Share an insight, caveat, or question.
Ippolito et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: